Mallinckrodt has begun a national rollout of the INOmax Evolve DS delivery system, which is FDA-cleared to provide inhaled nitric oxide to certain neonatal ICU patients in order to improve oxygenation and reduce the need for extracorporeal membrane oxygenation.